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ABSTRACT  
Silk has a robust clinical track record and is emerging as a promising biopolymer for drug 
delivery, including its use as a nanomedicine. However, silk-based nanomedicines still require 
further refinements for full exploitation of their potential; the application of ÒstealthÓ design 
principals is especially necessary to support their evolution. The aim of this study was to develop 
and examine the potential of PEGylated silk nanoparticles as an anticancer drug delivery system. 
We first generated B. mori derived silk nanoparticles by driving β-sheet assembly (size 104±1.7 
nm, zeta potential Ð56±5.6 mV) using nanoprecipitation. We then surface grafted polyethylene 
glycol (PEG) to the fabricated silk nanoparticles and verified the aqueous stability and 
morphology of the resulting PEGylated silk nanoparticles. We assessed the drug loading and 
release behaviour of these nanoparticles using clinically established and emerging anticancer 
drugs. Overall, PEGylated silk nanoparticles showed high encapsulation efficiency (>93 %) and 
a pH-dependent release over 14 days. Finally, we demonstrated significant cytotoxicity of drug 
loaded silk nanoparticles applied as single- and combination nanomedicines to human breast 
cancer cells. In conclusion, these results, taken together with prior silk nanoparticle data, support 
a viable future for silk-based nanomedicines. 
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INTRODUCTION 
The term ÒnanomedicineÓ was coined in the early 2000s and is essentially an umbrella 
descriptor for specifically engineered, nanosized therapeutics and imaging agents composed of 
multiple components 1. Over the past three decades, more than 40 nanomedicines have entered 
routine clinical use 1, 2. The majority of these nanomedicines serve as imaging agents 1, 2, but 
interest continues in nanomedicines for drug delivery applications 3. For example, more than a 
dozen nanoparticles are currently in clinical trials for a broad spectrum of indications 4, 5, 
including targeting of solid tumours 6. Nanoparticles are particularly well suited for tumour 
targeting because they can exploit the leaky neo-vasculatures and poor lymphatic drainage of 
solid tumours, thereby enabling their passive accumulation 7, 8. This phenomenon is widely 
described as the enhanced permeation and retention effect (EPR) 9; this effect can increase the 
retention time of nanoparticles in tumours 10.  
 
The payloads of nanomedicines differ widely but they must reach the tumour 
microenvironment and often must deliver their payload to a specific intracellular compartment to 
elicit the desired pharmacological effect 11. For example, anticancer nanomedicines designed for 
intracellular activation must complete their journey from the extracellular space to the desired 
intracellular destination via endocytic pathways 12, 13. Following endocytic uptake of a 
nanomedicine, the default destination is the lysosome, where the nanomaterial is exposed to low 
pH (typically 4.5) and lysosomal enzymes 14. The use of stimulus-responsive polymers (e.g. pH-
triggered) in the design of the macromolecular drug carrier can therefore promote drug release 
(i.e. lysosomotropic drug delivery) 15. 
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The vast majority of anticancer nanomedicines are designed for parenteral administration, 
which means that the nanomedicine must come into direct contact with the blood. This can 
trigger nanomedicine opsonisation; a process that is one of the most significant biological 
barriers for controlled drug delivery 16. Specifically, unmodified nanomedicines are ÒtaggedÓ by 
opsonins, subsequently recognized by the mononuclear phagocytic system (MPS) and eventually 
removed 16. Therefore, surface modification of macromolecular drug carriers is a well-
established strategy to minimise this effect 17, 18. Surface modification of particles provides many 
benefits: increased biocompatibility, decreased immune response, improved stability and delayed 
clearance by the MPS 18, 19. Therefore, PEGylated nanoparticles have a greater chance of reaching 
the tumour microenvironment when compared to uncoated nanoparticles 18, 20.  
 
Biopolymers ranging from biological active polymers (e.g. heparin) to macromolecular drug 
carriers (e.g. dextrin, dextran, alginates, chitosan) and multifunctional materials 21, 22 are being 
used for a broad spectrum of medical applications. One natural biopolymer, silk, has been used 
for many centuries for suturing, and is licensed by the Food and Drug Administration (FDA) for 
use in humans for load bearing applications. Nevertheless, silk has only recently emerged as 
promising biopolymer for drug delivery 23.  
 
Silk has a robust clinical track record and excellent mechanical properties 23, 24. In addition, silk 
is biodegradable, and can be processed under mild aqueous conditions to generate various 
material formats 25. A number of studies have detailed the manufacture of Bombyx mori silk 
nanoparticles using polyvinyl alcohol blends (particle size range 300 nm to 10 μm) 26, 
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emulsification ( >6,000 nm) 27, capillary microdot printing (25 to 140 nm) 28, salting out (486 to 
1,200 nm) 29, supercritical CO2 (50 - 100 nm) 
30, 31 or organic solvent precipitation (35 to 170 nm) 
32-34 (reviewed in 35). Some of these studies examined the ability of silk nanoparticles to entrap 
and release (model) drugs 26, 29, 32. Nanoparticles prepared from spider silks 36, 37 and chimeric silks 
(e.g. silk-elastinlike protein polymers) 38 are typically formed using a self-assembly process; 
these engineered silk nanoparticles have been used for a range of drug delivery applications 
including small molecular weight (model) drugs 39 and biologics (e.g. peptides, proteins and 
therapeutic plasmids) (reviewed in 40, 41). For example, bioengineered spider silk nanoparticles 
functionalized with a HER2 binding peptide and loaded with doxorubicin showed preferential 
uptake via receptor-mediated endocytosis in HER2+ breast cancer cells resulting in improved 
intracellular drug delivery when compared to non-targeted nanoparticles 42. However, none of the 
described silk nanoparticles has been specifically refined to avoid the MPS. The optimum use of 
nanoparticles in vivo, however, typically requires ÒstealthÓ design principals. Therefore, the aim 
of this study was to manufacture PEGylated silk nanoparticles and characterise their drug 
loading and drug release characteristics, coupled with preliminary in vitro studies. 
 
Material and Methods  
Preparation of silk nanoparticles 
Bombyx mori silk was extracted from cocoons as described previously 43. Briefly, cocoons 
were cut into 5 x 5 mm pieces, boiled in 0.02 M Na2CO3 for 60 min, and then fibres were rinsed 
in ddH2O and air dried. The fibres were then dissolved in 9.3 M LiBr solution at 60 ¼C, yielding 
a 5 wt% solution. This solution was dialysed (molecular weight cut-off 3,500) against ddH2O for 
72 h to remove the LiBr salt. The resulting aqueous silk solution was cleared by centrifugation.  
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Silk nanoparticle preparation has been reported elsewhere 33. Briefly, the silk (5 wt%) solution 
was added dropwise (20 μl/drop) to acetone, maintaining > 75 %v/v acetone volume. 
Precipitated silk was then centrifuged at 48,400 × g for 2 h, the supernatant was aspirated and the 
pellet was re-suspended in ddH2O, vortexed, and subsequently sonicated twice for 30 s at 30 % 
amplitude with a Sonoplus HD 2070 sonicator (Ultrasonic homogenizer, Bandelin, Berlin, 
Germany). The centrifugation, washing and re-suspension steps for the silk nanoparticle 
preparation were repeated at least twice more. The particles were analysed as detailed below and 
stored at 4 ¼C until use. 
 
Preparation of PEGylated silk nanoparticles 
For PEGylation, an aqueous 50 mg/ml silk nanoparticle stock was prepared. Next, 50 mg of 
silk nanoparticles and 50 mg of methoxypolyethylene glycol activated with cyanuric chloride 
(TST-activated mPEG, 5,000 g/mol, Sigma-Aldrich, St. Louis, MO, USA) were allowed to react 
in 2 ml of 50 mM Na2B4O7 pH 9.4 overnight under constant stirring at 4¼C. After the reaction, 
the sample was centrifuged for 30 minutes at 194,000 × g. The absorbance of the collected 
supernatant was measured at 240 nm 44. A calibration curve of activated PEG in 50 mM Na2B4O7 
was used to determine the amount of PEG conjugated to silk nanoparticles. 
 
Silk nanoparticle size and zeta potential analysis 
Particle size and zeta potential of native and PEGylated silk nanoparticles were determined by 
dynamic light scattering (DLS, Zetasizer Nano-ZS Malvern Instrument, Worcestershire, UK) in 
ddH2O unless otherwise stated. Refractive indices of 1.33 for ddH2O and 1.60 for protein were 
 7 
taken for computation of particle size. The native and PEGylated silk nanoparticles were stored 
at 25 ¼C and zeta potential and size were determined at day 0 and 28. The impact of pH on the 
zeta potential of native and PEGylated silk nanoparticles was determined by suspending them in 
0.01 M phosphate buffer saline (PBS) at pH 4.5 to 8.5 and measuring the resulting zeta potential. 
For stability and aggregation studies SNPs and PEG-SNPs particles were added to 0.1 M 
phosphate buffer and DLS measurements were performed. 
 
Scanning electron microscopy (SEM) was used to visualise particles. Native and PEGylated 
silk nanoparticles were diluted with distilled water to a concentration of 1 mg/ml. The samples 
were then pipetted onto a silicon wafer and lyophilized overnight. The specimens were sputter-
coated with 20 nm of gold using ACE200 Low Vacuum Sputter Coater (Leica Microsystems, 
Wetzlar, Germany) and analysed with a FE-SEM SU6600 (Hitachi High Technologies, Krefeld, 
Germany) at 5 kV and a 40,000-fold magnification. 
 
Fourier Transform Infrared Spectroscopy (FTIR) 
Fourier transform infrared spectroscopy (FTIR) was carried out using a PerkinElmer Spectrum 
100 instrument over the wavenumber range of 550 to 4000 cm-1. All spectra were normalized and 
corrected for water signals. OriginPro 9.0 software was used to peak fit the amide I region of all 
spectra. Peak full width at half maximum (FWHM) was maintained at a fixed value to avoid 
over-fitting the data 45. Untreated silk film, autoclaved silk film, freeze dried native and 
PEGylated silk nanoparticles were used to determine the secondary structure of silk and assigned 
as detailed elsewhere 46. Briefly, the amide I region (1595Ð1705 cm-1) was identified and 
deconvoluted: 1605Ð1615 cm-1 as side chain, 1616Ð1637 cm-1 and 1697Ð1703 cm-1 as β-sheet 
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structure, 1638Ð1655 cm-1 as random coil structure, 1656Ð1662 cm-1 as α-helical bands and 
1663Ð1696 cm-1 as β-turns. Silk films with a low and high crystallinity were generated as 
detailed previously 47 and used as a reference for silk nanoparticles.  
 
Drug loading of silk nanoparticles 
The drug loading strategy used for doxorubicin (LC Laboratories, Boston, MA, USA) and 
propranolol (Sigma-Aldrich, St. Louis, MO, USA) was identical for native and PEGylated silk 
nanoparticles. Briefly, a 200 μl nanoparticle suspension containing 10 mg of silk nanoparticles 
was mixed with 200 nmol drug in 1 ml of ddH2O. After a 24 h incubation period at room 
temperature, the sample was centrifuged for 30 min at 194,000 × g. The supernatant was 
collected and the pellet was washed three times with ddH2O. The combined supernatant was 
analysed for free drug in order to determine the encapsulation efficiency (%) and weight 
percentage (%w/w) loading. With the aid of propranolol and doxorubicin calibration curves the 
amount of free drug remaining in solution was calculated using absorbance (289 nm) and 
fluorescence (excitation 480 nm, emission 590 nm) measurements, respectively. Subtracting the 
residual amount left in the supernatant from the initial starting amount allowed us to deduce 
nanoparticle drug loading. The encapsulation efficiency was calculated using equation (1): 
(1) Encapsulation efficiency (%) = W1 × 100 
                                                               W2 
where W1 is the actual nanoparticle drug loading and W2 is the theoretical nanoparticle drug 
loading.   
 
In vitro drug release from silk nanoparticles 
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Drug loaded nanoparticles were re-suspended in 0.5 ml of PBS at pH 4.5, 6.0 and 7.4. The 
samples were then loaded into a 0.1ml Slide-A-Lyzer Mini Dialysis Device (MWCO 3500 g mol-
1; Thermo Scientific, Waltham, MA, USA) that was inserted into a 1.5 ml receiving chamber 
containing 1 ml of buffer at the indicated pH and then incubated at 37¼C. At the indicated time 
points, the propranolol or doxorubicin in the receiving chamber was monitored using UV-VIS-
spectroscopy (289 nm) or fluorescence spectroscopy (excitation 480 nm, emission 590 nm), 
respectively. At each measuring interval, all buffer was replaced with fresh buffer to ensure that 
sink conditions were maintained throughout the study. Calibration curves of the drugs at the 
indicated pH of 4.5, 6.0 or 7.4 were used to quantify drug release. The percentage of cumulative 
model drug release (%) was determined as a function of incubation time. Equivalent amounts of 
freely diffusible propranolol and doxorubicin were used to estimate diffusion-dependent effects 
of the release setup; at the indicated time points samples were analyzed as detailed above.  
 
In vitro response of macrophages towards silk nanoparticles 
The murine macrophage RAW 264.7 cell line was purchased from ATCC (Manassas, VA, 
USA). Cells were cultured in DMEM (4.5 g glucose, 110 mg sodium pyruvate, 10 %v/v FBS), 
grown in a humidified 5 % CO2 atmosphere at 37¡C and routinely subcultured every 2Ð3 days by 
scraping cells off the flask and re-plating them at a split ratio of 2 to 10 on tissue culture treated 
polystyrene (Corning, New York, NY, USA). Macrophage activation was assessed by seeding 
the cells at a density of 1.4 x 104 cells/cm2 and allowing them to recover overnight. Next, the 
culture medium was aspirated and replaced with fresh containing either (i) 5 ng of 
lipopolysaccharide (LPS, Sigma-Aldrich, St. Louis, MO, USA), (ii) 50 μg of native silk 
nanoparticles, (iii) 50 μg of PEGylated silk nanoparticles and (iv) control medium. Cultures were 
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incubated for 24 h and then the medium was collected and centrifuged at 6,000 × g for 5 minutes. 
Assay samples were stored at -80 ¡C and analyzed using mouse tumor necrosis factor alpha 
(TNF-α) DuoSet ELISA (R&D Systems, Minneapolis, MN, USA), according to the 
manufacturerÕs instructions. 
 
In vitro cytotoxicity and analysis of freely diffusible drug combinations  
The human breast cancer cell lines MCF-7 was purchased from ATCC (Manassas, VA, USA). 
Cells were cultured in DMEM (4.5 g glucose, 110 mg sodium pyruvate, 10 %v/v FBS, 10 μg/ml 
insulin), plated on tissue culture treated polystyrene, grown in a humidified 5 % CO2 atmosphere 
at 37¡C and routinely subcultured every 2Ð3 days. Cells were seeded in 96-well plates at a 
density of 2 x 104 cells/cm2 and allowed to recover overnight. Next, propranolol and doxorubicin 
stock solutions were filter sterilized (0.22 µm, PES membrane, Merck Millipore, Billerica, MA, 
USA) and cells were treated using freely diffusible (i) doxorubicin, (ii) propranolol and (iii) 
doxorubicin and propranolol combinations (Supplementary Fig. 4). Following a 72 h incubation 
period during the exponential growth phase, cell viability was determined using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT at 5 mg/ml in PBS); 20 µl of MTT 
was added to each well and cultures were incubated for 5 h. The formazan product was 
solubilized with 100 µl of dimethylsulfoxide and absorbance was measured at 570 nm. Untreated 
control cells represented 100 % cell viability. For treatment groups the half maximal inhibitory 
concentration (IC50) was calculated. 
 
The impact of freely diffusible doxorubicin and propranolol drug combinations on MCF-7 
cells was determined with an isobologram and combination-index methods using CompuSyn 
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Software (ComboSyn Inc., Paramus, NJ, USA). First, the IC50s for each drug on its own was 
determined as detailed above. Next, an isobologram was generated by plotting the propranolol 
IC50 on the abscissa and doxorubicin IC50 on the ordinate. The straight line fit connecting these 
IC50 values generated the additive line. Combination data points that fell on the line represented 
an additive effect, while data points that fell below or above the line represented synergism or 
antagonism, respectively. The combination index (CI) of doxorubicin and propranolol was 
calculated with CompuSyn Software (version 1.0), where a CI<1 indicated synergism, CI = 1 
was additive and CI > showed antagonism 48. The most promising drug combination was used for 
nanoparticle experiments. 
 
In vitro cytotoxicity of drug loaded silk nanoparticles  
Combination therapy delivered via native and PEGylated silk nanoparticles used fixed ratios of 
0.01 µg doxorubicin and 2.1 µg of propranolol for every 0.5 mg of silk nanoparticles. 
Nanoparticles were prepared as detailed above and loaded with the respective drug (100% 
loading efficiency). Next, doxorubicin loaded nanoparticles and propranolol loaded nanoparticles 
were mixed to obtain the desired doxorubicin and propranolol combination. MCF-7 cells were 
cultured as detailed above and cells were treated with (i) 0.5 mg native silk nanoparticles, (ii) 0.5 
mg PEGylated silk nanoparticles, (iii) 0.5 mg silk nanoparticle containing the fixed drug 
combination of 0.01 µg doxorubicin and 2.1 µg propranolol, or (iv) the combination of freely 
diffusible drugs at the equivalent doses. Following a 72 h incubation period cell viability was 
assessed with the MTT as detailed above.  
 
Scanning electron microscopy of MCF-7 cells exposed to drug loaded silk nanoparticles  
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MCF-7 cells were seeded on glass coverslips and allowed to recover as detailed above. Cells 
were exposed to the treatments for 72 h and then fixed with 2 %v/v glutaraldehyde in PBS, 
washed with ddH2O twice, dehydrated and critical point dried (EM CPD300, Leica 
Microsystems, Wetzlar, Germany) as detailed elsewhere 49. Samples were then sputter-coated 
with 15 nm of gold and analysed by SEM at 5 kV at 300, 700 and 2,000 fold magnification. 
Counts of MCF-7 neighboring cells were determined manually and plotted using histograms.  
 
Labeling Silk Nanoparticles with Alexa Fluor 488   
A total of 10 mg of native and PEGylated silk nanoparticles were fluorescently labelled. First, 
silk nanoparticles were resuspended in 0.1 M NaHCO3, pH 8.3. Next, 1 mg of Alexa Fluor 488 
succinimidyl ester (Life Technologies, Carlsbad, CA, USA) was dissolved in anhydrous 
dimethylsulfoxide (DMSO) at 1 mg/ml and 100 μL of this solution was added to the native and 
PEGylated silk nanoparticles and allowed to react for 24 h at room temperature in the dark while 
stirring. Silk nanoparticles were then centrifuged and the pellets were washed 4 times with 
acidified water (pH 4.6) to remove unbound dye, followed by 3 washes with ddH2O. The 
samples were stored at 4 ¡C in the dark until use.  
 
Cellular uptake of native and PEGylated silk nanoparticles 
MCF-7 cells were seeded in complete phenol red-free medium at a density of 2 × 104/cm2 and 
allowed to recover for 24 h. Next, the cultures were incubated for 5 h with: (i) 0.3 μg/ml 
doxorubicin or the equivalent amount of doxorubicin loaded in (ii) 0.5 mg/ml Alexa Fluor 488 
labelled native silk nanoparticles, or (iii) 0.5 mg/ml Alexa Fluor 488 labelled PEGylated silk 
 13 
nanoparticles. Immediately prior to live cell imaging, the culture medium was replaced with 
fresh complete DMEM medium containing 25 mM HEPES. Cells were imaged for up to 20 
minutes using a Leica TCS-SP5 confocal laser scanning microscope (Leica Microsystems 
GmbH, Wetzlar, Germany) equipped with a 40× magnification water objective with a numerical 
aperture of 1.25. Alexa Fluor 488 and doxorubicin-associated fluorescence was tracked using a 
485 nm excitation wavelength and acquired sequentially to minimize bleed-through at an 
emission wavelength of 500Ð545 nm and 590Ð635 nm, respectively. The data were exported to 
Image J 1.48 (National Institute of Health, USA) for contrast enhancement and were assembled 
for co-localization. 
 
Statistical analysis 
Data were analyzed using GraphPad Prism 5.0b (GraphPad Software, La Jolla, CA, USA). 
Sample pairs were analyzed with the Student's t-test. Multiple samples were evaluated by one-
way analysis of variance (ANOVA) followed by BonferroniÕs multiple comparison post hoc test. 
An asterisk denotes statistical significance as follows: *P < 0.05, **P < 0.01, ***P < 0.001. All 
data are presented are as mean values ± standard deviation (SD) and n reverse to the number of 
independent experiments. 
 
Results 
Characterisation of PEGylated silk nanoparticles 
Nanoprecipitation generated uniform silk nanoparticles that were of a spherical size (104.20 
nm ± 1.7, polydispersity 0.11) and had a net negative charge, resulting in a zeta potential of -
56.38 mV ± 5.6 in water (Table 1). The presence of amine, hydroxyl and imidazole groups in the 
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silkÕs primary structure rendered this biopolymer amenable to TsT-activated mPEG conjugation 
(Fig. 1a). Here, silk nanoparticles were PEGylated using activated PEG and the process was 
tailored to maximize yields. Pilot studies used a constant weight-based 1:1 ratio of activated PEG 
to silk nanoparticles, employing 20 mg and 50 mg silk nanoparticle batch sizes. The amount of 
surface-grafted PEG was significantly higher (P<0.05) for the 50 mg silk nanoparticle batch 
(19.4 ± 1.93 %) than for the 20 mg batch (12.1 ± 2.2 %) (Fig. 1b). Therefore, a 50 mg silk 
nanoparticle batch size was routinely used for all subsequent studies. In addition to 
spectrophotometric measurements to quantify PEGylation, the impact of PEGylation on particle 
size and zeta potential was measured (Table 1). PEGylation significantly increased the apparent 
size of the silk nanoparticles from 104.2 nm to 116.4 nm (Fig. 1c), and significantly decreased 
the negative surface charge from -56.38 mV to -46.71 mV (paired t-test, P<0.001) (Table 1).  
 
Table 1 Summary of silk nanoparticle characteristics. Data sets are ±SD, n ≥ 3.  
Sample Particle size (nm) PDI Zeta potential (mV)# 
SNPs 104.20 ± 1.70 0.11 ± 0.01 -56.38 ± 5.60 
PEG-SNPs 116.40 ± 3.23 0.12 ± 0.02 -46.71 ± 2.59 
# Measurements were performed in ddH2O 
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Figure 1. Formation and characterisation of PEGylated silk nanoparticles. (A) The reaction 
between activated PEG and the silk nanoparticle surface. (B) PEG grafting efficiency to the silk 
nanoparticle surface for 20 mg/ml and 50 mg/ml batches (equivalent to 20 mg and 50 mg of silk, 
respectively). Paired t-test, *P<0.05, ±S.D, n = 3.  (C) A schematic representation of native (left) 
and PEGylated silk nanoparticles (right). Diagram not drawn to scale. 
 
Surface analysis of native and PEGylated silk nanoparticles  
Zeta potential measurements over a range of pH were used to study surface charge 
characteristics of native and PEGylated silk nanoparticles. The zeta potentials of PEGylated silk 
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nanoparticles were not substantially different over the pH 4.5 to 8.5 range. In contrast, the 
surface charges of unmodified silk nanoparticles were sensitive to ion exchange; this was evident 
as they became more strongly charged at higher pH values (Fig. 2a). The FTIR spectra of the 
amide I region of native and PEGylated silk nanoparticles were compared to untreated and 
autoclaved silk films and PEG (Fig. 2b). The PEGylated silk nanoparticle secondary structure 
was dominated by β-sheets. In turn, PEGylated silk nanoparticles had the lowest α-helices and 
turns content of all studied samples. Overall, spectra of native and PEGylated silk nanoparticles 
showed a high β-sheet content and substantially lower α-helix and random coil structures when 
compared to untreated, water-soluble silk films (Supplementary Fig. 1). 
 
 
 
Figure 2. Characteristics of native and PEGylated silk nanoparticles. (A) Zeta potential 
measurements for silk nanoparticles in 0.01 M PBS at pH 4.5 to 8.5. (B) FTIR absorbance 
spectra of native and PEGylated silk nanoparticles and reference samples; (a) PEGylated silk 
nanoparticles; (b) silk nanoparticles; (c) autoclaved silk films; (d) untreated silk films and (e) 
PEG. Dashed line indicates β-sheet.  
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In vitro stability studies of native and PEGylated silk nanoparticles 
Native and PEGylated silk nanoparticles were prepared and stored for up to 28 days in ddH2O 
at 25¼C and subjected to particle size, zeta potential and SEM analysis. During the 28 day storage 
period, no significant changes were noted in the particle size and zeta potential of the native and 
PEGylated silk nanoparticles (P>0.05) (Fig. 3a). Qualitative studies by SEM showed that the 
native and PEGylated silk nanoparticles were able to maintain their spherical shapes and particle 
size (100-120 nm) in suspension (Fig. 3b). Exposure of silk nanoparticles to phosphate buffer 
induced time-dependent aggregation of native silk nanoparticles, resulting in >400 nm particle 
aggregates within 20 minutes (Fig. 3c). In contrast, PEGylated silk nanoparticles showed no 
signs of aggregation and retained their size throughout the study period (Fig. 3 c,d).  
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Figure 3. Assessment of native and PEGylated silk nanoparticles. (A) Impact of storage 
temperature and time on native and PEGylated silk nanoparticle size and zeta potential (±SD, 
n=3). (B) SEM images of native and PEGylated silk nanoparticles stored at 25¼C for 4 weeks 
(scale bar 1 μm) (C) Particle size of SNPs and PEG-SNPs exposed to 0.1 M phosphate buffer at 
0 to 60 minutes post exposure and their (D) qualitative assessment at 0, 1 h and 24 h (scale bar 2 
cm). Samples are presented in micro-cuvettes and representative images are shown. At 24 h the 
native silk nanoparticle suspension showed phase separation with nanoparticle aggregation at the 
top and bottom of the cuvette. 
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Figure 4. Macrophage response to silk nanoparticles. Quantification of tumor necrosis factor 
alpha (TNF-α) in culture supernatants following 24 h exposure to 5 ng of lipopolysaccharide 
(LPS, positive control), 50 μg of native or PEGylated silk nanoparticles and untreated control 
cells (basal TNF-α levels). (Significant differences were determined with ANOVA, followed by 
BonferroniÕs multiple comparison post hoc test ***P< 0.001, ±SD, error bars are hidden in the 
plot-symbol when not visible, n=3).  
 
PEGylated silk nanoparticles: Modulating macrophage response  
The macrophage response to native and PEGylated silk nanoparticles was determined by 
quantifying the secreted amounts of TNF-α in the culture medium (Fig. 4). While native silk 
nanoparticles induced a significant amount of TNF-α release, PEGylated silk nanoparticles 
showed no differences in secreted TNF-α levels when compared to negative control 
macrophages. Overall, the highest macrophage response was observed for LPS stimulated cells.  
 
Silk nanoparticles: Drug loading and release  
Pilot studies were conducted using 200 nmol propranolol and 20, 50 and 100 mg silk 
nanoparticles to determine silkÕs loading and encapsulation efficiency (Fig. 5a, b). The 
encapsulation efficiency of 20 mg silk was 46 %, which was significantly lower than that of 50 
mg and 100 mg of silk nanoparticles, where 93 % and 98 % of the drug was adsorbed, 
respectively (Fig. 5b). No statistically significant difference was found between 50 and 100 mg 
silk nanoparticles, so all subsequent studies were conducted with 50 mg. The overall propranolol 
loading profile for 50 mg of silk nanoparticles indicated a 50 % loading efficiency for 1,420 
nmol propranolol (Supplementary Fig. 2). We next determined the loading capacity of 
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PEGylated silk nanoparticles. A 50 mg sample of PEGylated silk nanoparticles showed 
significantly better propranolol loading than 20 mg of PEGylated silk nanoparticles (Fig. 5b). 
The use of 50 mg of PEGylated silk nanoparticles increased the loading efficiency for 
propranolol from 93 to 98 % when compared to native silk nanoparticles (Fig. 5b). The use of 50 
mg of both native and PEGylated silk nanoparticles resulted in loading of 100 % of 200 nmol 
doxorubicin (Fig. 5c).  We also examined the influence of the adsorbed payload on particle size 
and zeta potential. The particle size of drug-loaded native and PEGylated silk nanoparticles did 
not change (data not shown). However, the zeta potential of drug-loaded native or PEGylated 
silk nanoparticles was significantly different when compared to that of the unloaded 
nanoparticles (Supplementary Fig. 3). 
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Figure 5. Characterisation of the loading capacity of native and PEGylated silk nanoparticles. 
(A) Loading efficiency (%w/w) and (B) encapsulation efficiency (%) for propranolol in relation 
to different amounts of silk nanoparticles. (C) Ability of native and PEGylated silk nanoparticles 
to adsorb doxorubicin. (Significant differences were determined with ANOVA followed by 
BonferroniÕs multiple comparison post hoc test and paired t-test, **P< 0.001, ±SD, error bars are 
hidden in the plot-symbol when not visible, n=3).  
 
 
The release behaviour of drug-loaded nanoparticles was studied over a range of pH to mimic 
the pH of blood plasma (pH 7.4), early endosomes (pH 6.0), and lysosomes (pH 4.5). For 
propranolol, almost 90 % of the drug was liberated from native or PEGylated silk nanoparticles 
after 4 days at pH 4.5 (Fig. 6a, b). Both particles types showed a similar release behaviour for 
propranolol at pH 7.4 and pH 4.5, while the slowest release of both particle types was found at 
pH 6.0. Overall, PEGylation of silk nanoparticles had very little impact on the release behaviour 
of propranolol at all studied pH values (Fig. 6a, b).  
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Figure 6. Cumulative drug release from silk nanoparticles. (A) Propranolol loaded silk 
nanoparticles, (B) propranolol loaded PEGylated silk nanoparticles, (C) doxorubicin loaded silk 
nanoparticles and (D) doxorubicin loaded PEGylated silk nanoparticles. (One-way ANOVA 
followed by BonferroniÕs multiple comparison post hoc test, *P<0.05, **P<0.001, ± SD; error 
bars are hidden in the plot-symbol when not visible, n = 3). 
 
The release of doxorubicin from native or PEGylated silk nanoparticles, on the other hand, 
showed extended release over 14 days (Fig. 6c, d). The release behaviour of the loaded 
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doxorubicin was pH dependent (pH 4.5>>6.0>7.4). About 50 % of the loaded doxorubicin was 
liberated after 14 days at pH 4.5 from native silk nanoparticles, while 50 % of the drug was 
released after 5 days at pH 4.5 from PEGylated silk nanoparticles (Fig. 6c, d). Doxorubicin-
loaded PEGylated silk nanoparticles provided a faster release rate by 24 h (16 % versus 6 %) and 
72 h (38 % versus 18 % at 3 days) and over the course of the study (81 % versus 50 % for 
PEGylated and native silk nanoparticles, respectively) (Fig. 6c, d).  Finally, control studies using 
equivalent doses of freely diffusible doxorubicin and propranolol showed negligible diffusion-
dependent effects for the employed release set-up (data not shown) and now fluorescence 
quenching. 
 
Silk nanoparticles for anticancer drug delivery: In vitro cytotoxicity  
The cytotoxicities of native and PEGylated silk nanoparticles were first determined using 
human breast cancer cells (Fig. 7a, b); both nanoparticle types had an IC50 > 5 mg/ml. Next, silk 
nanoparticles loaded either with propranolol or doxorubicin were assessed as mono-therapy and 
as a combination therapy. As controls, analogous experiments with equivalent dose levels and 
combinations were preformed with unbound, freely diffusible drug. Dose-response curves were 
established for the freely diffusible drugs and the half maximal inhibitory concentration (IC50) 
was calculated for each drug. These IC50s were used to assess freely diffusible drug combinations 
with an isobologram and gave a subsequent CI value of 0.94 for the doxorubicin (0.1 µg/ml) and 
propranolol (21 µg/ml) drug combination (Supplementary Fig. 4 b).  
 26 
 
Figure 7. In vitro cytotoxicity of silk nanoparticles against human breast cancer cells. MCF-7 
breast cancer cells were exposed for 72 h to (A) silk nanoparticles, (B) PEGylated silk 
nanoparticles and (C) doxorubicin (0.01µg) and propranolol (2.1 µg) drug combination of freely 
diffusible and nanoparticle delivered drug combinations. (One-way ANOVA followed by 
BonferroniÕs multiple comparison post hoc test, *P<0.05, ± SD, n = 3). 
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The data sets obtained for freely diffusible drug combinations were then used to inform 
nanoparticle studies. First, silk nanoparticles were loaded with either propranolol or doxorubicin, 
next drug loaded silk nanoparticles were mixed to yield the most promising drug combination 
(i.e. 0.01 μg doxorubicin and 2.1 μg propranolol) that was then tested in vitro. The combination 
of propranolol- and doxorubicin-loaded silk nanoparticles significantly reduced cell viability 
when compared to the equivalent amount of doxorubicin (Fig. 7c). The greatest reduction in cell 
viability was observed for drug loaded PEGylated silk nanoparticles; they outperformed the 
freely diffusible treatment groups and showed a significant greater cytotoxicity than drug loaded 
native silk nanoparticles (Fig. 7c). These cytotoxicity measurements were underpinned by SEM 
analysis of MCF-7 (Fig. 8). Cells exposed to doxorubicin- and propranolol-loaded native and 
PEGylated silk nanoparticles showed substantial morphological changes when compared to 
control cells (Fig. 8 a-h).  Control MCF-7 cells had a large number of plasma membrane 
microvilli (Fig. 8e and i) that were not found in drug-treated cells; overall, the drug-treated cells 
had a smoother appearance (Fig. 8 f-h), with evidence of plasma membrane-associated native 
and PEGylated silk nanoparticles (Fig. 8 g, h). SEM images were quantitatively analyzed by 
determining the number of cell neighbors (Fig. 8 j). Cells treated with either freely diffusible 
drug or the silk nanoparticle-drug combination showed a similar reduction in neighboring cells 
when compared to untreated cells (Fig. 8j).  
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Figure 8. Scanning electron microscopy of human breast cancer cells exposed to drug 
combinations. (A, E, I) MCF-7 control cells displaying typical cluster-like arrangements with 
plasma membrane microvilli (arrows E and I). Cells treated with the drug combination of (B, F) 
freely diffusible propranolol (2.1 µg) and doxorubicin (0.01 µg) and the drug combination at the 
equivalent amounts delivered using (C, G) native and (D, H)  PEGylated silk nanoparticles. (J) 
Qualitative analysis of cell neighbors; MCF-7 control cells, cells treated with the freely diffusible 
drug combination and the drug combination at the equivalent doses delivered using silk 
nanoparticles.  
 
 
Cellular uptake of native and PEGylated silk nanoparticles 
The intracellular distribution of doxorubicin-loaded native and PEGylated silk nanoparticles 
was visualized by confocal live cell imaging. Native silk nanoparticles had a propensity to form 
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aggregates in the culture medium, resulting in substantial amounts of doxorubicin-loaded silk 
nanoparticles attaching to the cell plasma membrane (Fig. 9a). Nonetheless, cytoplasmic 
doxorubicin and both doxorubicin- and nanoparticle-associated fluorescence were evident in 
endocytic vesicles (Fig 9a-d). In contrast, doxorubicin-loaded PEGylated silk nanoparticles 
showed no aggregation and extensive perinuclear accumulation was evident in endocytic vesicles 
following a 5 h incubation. Furthermore, tracking of the doxorubicin-associated fluorescence 
showed substantial doxorubicin-associated fluorescence in the nucleus (Fig. 9g), but no 
nanoparticle-associated fluorescence (Fig. 9 f).  
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Figure 9. Live cell confocal fluorescence microscopy of doxorubicin-loaded native and 
PEGylated silk nanoparticles in MCF-7 cells. Cells were incubated with Alexa Fluor 488 
labelled nanoparticles for 5 h and imaged for doxorubicin-associated and nanoparticle-associated 
fluorescence. (A - D) Doxorubicin loaded native silk nanoparticles and (E - H) PEGylated silk 
nanoparticles. Asterisk (*) denotes doxorubicin accumulation in the nucleus. The scale bars for 
low and high magnification are 10 and 50 μm, respectively. 
 
Discussion 
Cancer therapy typically uses drug combinations to maximise clinical outcomes. Many 
anticancer drugs are small molecular weight compounds, where pharmacokinetics, tissue 
distribution, intracellular drug concentrations and elimination are governed by the 
physicochemical properties of the drug. Drug administration is typically based on the maximum 
tolerated dose and drug combinations are often concocted using this principal. However, 
emerging evidence suggests that cellular drug concentrations are critical for maximising any 
synergistic effects, because drug combinations can vary from antagonistic to synergistic 50. For 
example, a liposomal preparation containing the synergistic 5:1 cyterabinine:daunorubicin molar 
ratio is in Phase II/III clinical trials (Celator Pharmaceuticals) 50. The use of this macromolecular 
drug carrier approach endows the payload with a pre-designed whole body, organ, cellular and 
subcellular pharmacokinetic profile.  
 
Besides using drugs that have known anticancer indications, an effort is ongoing to repurpose 
other drugs for use in oncology 51. Emerging evidence indicates that β-adrenergic signalling 
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regulates multiple cellular processes, including cell proliferation, differentiation and migrationÑ
pathways that are implicated in cancer. Epidemiological studies also suggest that β-blockers 
favourably affect cancer progression and metastasis in patients 52. Therefore, this present study 
set out to determine the ability of silk nanoparticles to deliver both propranolol and doxorubicin 
in combination. However, the development of a combination nanomedicine that would also be 
applicable in in vivo applications first required refinement of the carrier to minimise MPS 
accumulation. 
 
PEGylation is one of the most popular ways to modify biomaterial surfaces. PEG is frequently 
used to modify macromolecular drug carriers such as nanoparticles and liposomes, as well as 
proteins, antibodies and aptamers 17, 18. The overall result of PEGylation is an improved 
pharmacokinetic profile when compared to the unmodified parent molecule. PEGylated 
macromolecules have been used clinically for more than 20 years with a remarkable safety track 
record 53. PEG is non-biodegradable and predominately eliminated via urinary clearance; 
therefore, the selected molecular weight must be below the renal threshold (typically < 30,000 
g/mol) to ensure adequate elimination 53.  
 
We used a linear 5,000 g/mol PEG because many clinical products employ this type of PEG 
molecule 53, 54. Cyanuric chloride-activated PEG (5000 g/mol) has previously been surface-
crafted for macro-scale silk films (18.9 cm2) using a reaction of cyanuric chloride to the amine 
and hydroxyl groups of silk 44 at a 1:2.5 silk:PEG ratio; this resulted in a grafting efficiency of 
3.5 %. These PEG grafted silk films displayed low cell adhesion when compared to the 
unmodified silk surface 44.  
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In pilot studies we varied both the silk:PEG ratio and the actual concentration of silk 
nanoparticles used during the conjugation reaction. Here, we selected a 1:1 silk:PEG ratio and a 
50 mg silk nanoparticle batch size, which resulted in 19.39 % grafted PEG. Although these 
conditions are quite different from the work reported for silk films 44, the final results are not 
surprising; the nanoscale nature of our particles substantially increases the relative surface area 
to mass and the overall dynamics of the conjugation reaction. We verified successful PEG 
grafting by physical measurements of nanoparticle size (104 nm and 116 nm for native and 
PEGylated silk nanoparticles, respectively) and zeta potential (-56 mV to -45 mV for native and 
PEGylated silk nanoparticles in ddH2O, respectively). These results are in line with the values 
reported in the literature because PEG is known to increase the apparent particle size and to 
shield surface charges 18, leading to a reduced zeta potential. Surface tethered PEG can adopt 
different configurations. For example, high PEG grafting densities typically leads to a brush like 
conformation while lower densities result in a mushroom like conformation 18. These different 
conformations are reflected in hydrodynamic layer thickness measurements. The radius of 
gyration (Rg) for PEG 5,000 g/mol is 2.8 nm 
55 and in the present study the measured 
hydrodynamic layer thickness was > 2 fold the Rg. This suggested that the most likely 
conformation of PEG chains extending from the surface of silk nanoparticles adopted a brush 
conformation 55. Although PEG reduced the zeta potential, the retention of some negative surface 
charge is desirable to provide sufficient electrostatic repulsion to prevent nanoparticle 
aggregation during storage and handling in addition to PEGsÕ ability to stabilize nanoparticles. 
Surface grafted PEG typically results in a more neutral zeta potential of nanoparticles (reviewed 
in 18); for example, PEGylated poly(lactic-co-glycolic acid) copolymer (PLGA) nanoparticles 
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showed effective charge reduction across a broad pH range 56.  In the present study the surface of 
PEG modified silk nanoparticles was effectively shielded from protonation and de-protonation 
over the studied pH range; an observation that was not made with native silk nanoparticles (Fig 
2a). Because the zeta potential is dependent on the solvent system used, the measured zeta 
potentials are different for those reported in Table 1 and Fig. 2a.  
 
We also confirmed the silk nanoparticle stability in water over 28 days, using both qualitative 
and quantitative measurements. The observation of stability of silk nanoparticles in water is 
encouraging because any drug carrier developed with a pharmaceutical application in mind needs 
to be sufficiently stable during storage (e.g. shelf life) and handling if it is to be a viable 
contender for subsequent clinical development.  
 
However, silk nanoparticles intended for parental administration come into contact with 
physiological fluids, not pure water. We therefore mimicked this contact by exposing silk 
nanoparticles to PBS and measuring the particle size (Fig. 3). The direct comparison of native 
and PEGylated silk nanoparticles clearly showed that surface grafted PEG was critical for 
stabilizing silk nanoparticles in PBS (Fig. 3c, d). Simple inclusion of PEG in the native silk 
particle solution (i.e., no covalent attachment to the surface) was not sufficient to achieve 
equivalent particle stability (data not shown).  
 
PEGylation to synthetic nanoparticles is typically supported by FTIR and/or nuclear magnetic 
resonance (NMR) analysis 18. Successful verification of this type of covalent linkage for the 
biopolymer silk is a recognized challenge 57; this also includes the reaction of cyanuric chloride-
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activated PEG with silk 44. We acknowledge that the lack of these measurements is a limitation 
of the current study, although the evidence presented (Table 1, Supplementary Fig. 1 and Fig. 1 
to 4) strongly suggests the successful covalent grafting of PEG onto silk nanoparticles. 
 
Next, we examined the macrophage response towards silk nanoparticles. Previous studies have 
clearly demonstrated that TNF-α release from macrophages in response to nanoparticles is a 
valuable marker for assessing the status of the MPS 58-60. The amount of TNF-α measured for the 
positive control was several fold higher than the levels determined for native silk nanoparticles 
(Fig. 4), whereas the macrophage response to native silk nanoparticles was comparable to that 
observed with PLGA nanoparticles (data not shown). More importantly, PEGylation of silk 
nanoparticles reduced the TNF-α amounts to levels seen with the untreated resting macrophages 
(Fig. 4). This clearly demonstrated that PEGylation of silk nanoparticles further improved their 
biocompatibility; the applied ÒstealthÓ technology successfully evaded the MPS system using the 
TNF-α assay. 
 
Next, we examined the ability of PEGylated silk nanoparticles to bind and release drugs. Silk 
carries a negative charge at pH 7.4 in both native and PEGylated form, as verified here, which 
facilitates loading of positively charged drugs via electrostatic interactions leading to an overall 
reduced zeta potential (Supplementary Fig 3). Propranolol (pKa 9.1) and doxorubicin (pKa 8.3) 
are weakly basic drugs that are protonated at a pH below their respective pKa values. The 
Scheibel laboratory demonstrated that the distribution coefficient (log D) and diffusion 
coefficient (log D MW-1) are two useful parameters for estimating the loading and encapsulation 
efficiency of weakly basic, small molecular weight molecules onto recombinant spider silk 
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(eADF4(C16)) particles 61. Log D is a useful indicator for predicting physical properties because 
it is based on the calculated ratio of unprotonated and protonated states of a molecule in octanol 
(hydrophobic) and water (hydrophilic), which in turn relates to both log P and pKa of the 
payload molecule.  
 
Our experiments supported the conclusion that eADF4(C16) particle loading was best for 
weakly basic payloads with a high log D and diffusion coefficient (expressed by the inverse 
proportionality of molecular weight). However, silk nanoparticles showed a greater 
encapsulation efficiency for doxorubicin than for propranolol at pH 7.4 despite a lower log D 
0.35 and logD MW-1 6 x 10-4 values than propanolÕs log D 1.47 and log D MW-1 5 x 10-3 values. 
This discrepancy is likely due to structural differences between B. mori silk and spider silk 
eADF4(C16). B. mori silk consists of hydrophilic blocks in the heavy chain with negative 
charges while spider silk eADF4(C16) is very hydrophobic due to its lack of hydrophilic spacers 
in the silk backbone 61. Therefore, structural differences in B. mori silk are likely to affect drug 
loading through a number of mechanisms, including hydrophilic-hydrophilic interactions and π-
π stacking of adsorbed doxorubicin resulting in high encapsulation efficiency. The work with 
eADF4(C16) 61 and this B. mori silk nanoparticle study used an equivalent amount of propranolol 
to silk. However, B. mori silk nanoparticles gave a 93 % propranolol encapsulation efficiency 
while eADF4(C16) particles encapsulated only 45 %. This discrepancy could be due to structural 
differences of the silks; this is also supported by the relatively high negative zeta potential (-56 
mV) of B. mori silk when compared to the low negative zeta potential (-22 mV) of eADF4(C16) 
of spider silk. Therefore, B. mori silk nanoparticles are expected to have a better drug loading 
capacity than eADF4(C16) spider silk systems. Overall, native and PEGylated B. mori silk 
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nanoparticles showed excellent drug loading capacity, which is a prerequisite for use as a drug 
delivery system.  
 
The EPR effect can provide a 50 to 100-fold accumulation of nanoparticles in the tumour 
microenvironment when compared to healthy tissues 7, 10. During the nanoparticle journey from 
the injection site to the tumour microenvironment, nanoparticles encounter various 
environmental conditions; the blood circulation, the extracellular space of the tumour 
microenvironment, and the subsequent endocytic uptake and trafficking to endosomes and 
lysosomes 14. Therefore, we examined drug release form PEGylated silk nanoparticles across a 
pH range that mimicked the conditions encountered in the blood (pH 7.4), early endosomes (pH 
6.0) and lysosomes (pH 4.5). The release profiles of propranolol and doxorubicin differed despite 
similar log D values across acidic pH (Fig. 6); pH dependent release of doxorubicin (pH 4.5>> 
6.5>7.4) correlated well with previous work 33. Here, we demonstrated that PEGylated silk 
nanoparticles retained this characteristic pH-dependent release profile with minimal doxorubicin 
release at pH 7.4. However, at acidic pH, doxorubicin release was significantly faster (approx. 2-
fold) from PEGylated silk nanoparticles than from native ones. Because PEGylated silk showed 
a reduced zeta potential when compared to native silk (-56.4 mV versus -46.7 mV), PEG grafting 
reduced the apparent acidic surface characteristics of silk. However, it is likely that PEGylation 
also changed the actual surface characteristics of the silk nanoparticles due to the reaction of 
cyanuric chloride with the silk imidazole, amine, and hydroxyl groups. This, in turn, is likely to 
reduce the drug-silk charge interactions, which are already less pronounced at a lower pH, 
cumulating in an even faster doxorubicin release. We speculate that drug release from silk 
nanoparticles is primarily governed by charge, although we cannot exclude other mechanisms of 
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PEG-mediated drug release, such as changes in hydrophilic-hydrophobic balance 62. In the 
current study, propranolol also showed a pH-dependent release. Interestingly, cumulative 
propranolol release at pH 6.0 was significantly lower than at pH 4.5 or 7.4. This is counter 
intuitive as arguably nearly all propranolol molecules are protonated at this pH. It can be clearly 
seen that for both PEGylated and non-PEGylated silk nanoparticles nearly 40 % of loaded 
propranolol remains bound to the silk nanoparticle (Fig. 6a,b) which would imply an interaction 
between propranolol and silk at this pH. Propranolol has shown to promote β-sheet formation in 
amyloids 45 and may interact with the β-sheet component of silk nanoparticles at this pH 
although further work is required to elucidate propranololÐsilk interactions.  
 
We next used human breast cancer cells to examine the ability of drug-loaded silk 
nanoparticles to deliver drug combinations. Emerging evidence suggests that propranolol has 
anticancer properties and synergistic effects are observed with chemotherapy. Furthermore, in 
vitro studies indicated that these effects were dose-dependent and cell-type specific 63. For 
example, increasing the concentration of 5 nM paclitaxel to 10 nM could modify the interaction 
effect from sub-additive to synergistic in MCF-7 human breast cancer cells when combined with 
10Ð50 µM propranolol 63; MCF-7 cells are luminal A with an immunoprofile of ER+, PR+/-, 
HER2- 64. However, this synergistic effect of paclitaxel and propranolol was not observed with 
HBL-100 cells (a putative human Ôbreast cancer cell lineÕ that has been discontinued) or SK-BR-
3 (invasive ductal carcinoma, ER-, PR-, HER+), where an antagonist dose-response was evident 
63. Based on these data we used MCF-7 cells to examine the biological response of doxorubicin 
and propranolol drug combinations. Freely diffusible drug combinations showed no synergism 
but an additive anticancer effect (Supplementary Fig. 4); a similar observation was made for silk 
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nanoparticle combinations. The lack of synergism is a limitation of the present study and 
requires additional optimization to uncover the full potential of silk nanoparticles for 
combination therapy. Nonetheless, combination therapy significantly reduced cell viability when 
compared to single drug treatment (Fig. 7) and changed MCF-7 morphology and organization 
(Fig. 8). Overall, PEGylated silk nanoparticle outperformed native silk nanoparticles for the 
delivery of single and combination therapy. One possibility for this observation is that 
PEGylated silk nanoparticles did not aggregate and thereby enabled efficient endocytic uptake 
and subsequent lysosomal accumulation of the carrier (Fig. 9). PEGylated silk nanoparticle 
delivering doxorubicin also induced greater cytotoxicity than freely diffusible controls at the 
equivalent doxorubicin concentration (Fig. 7c). This observation is encouraging but unexpected. 
Typically nanomedicines designed for intracellular activation do not show their full potential in 
vitro because cellular uptake is restricted to endocytosis (i.e. an energy dependent process that 
has a limited cargo uptake capacity) and the lack of EPR-mediated targeting 14.  
   
We report preliminary uptake studies of silk nanoparticles into MCF-7 breast cancer cells 
using live cell confocal microscopy. Live cell imaging was preformed to minimize the fixation 
artefacts typically seen with doxorubicin 12. Furthermore, we used a 5 h incubation time to allow 
the accumulation of silk nanoparticles throughout the entire endocytic pathway. Default 
trafficking from the plasma membrane into lysosomes typically takes 1 h 13, so additional time 
was allowed to provide sufficient exposure of silk nanoparticles to the low lysosomal pH. Images 
obtained for PEGylated silk nanoparticles clearly suggested lysosomotropic drug delivery 
because perinuclear accumulation of drug loaded silk nanoparticles was evident, in addition to 
exclusive doxorubicin-associated fluorescence in the nucleus (Fig. 9e-h). Overall, PEGylated silk 
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nanoparticles showed little plasma membrane binding, in contrast to native silk nanoparticles. 
PEGylation minimized nanoparticle aggregation in the culture medium (Fig. 3c, d) and thereby 
modulated endocytic uptake and lysosomal trafficking of discrete silk nanoparticles. These 
observations are in line with other studies describing the PEGylation of nanoparticles 65. 
  
Conclusion 
In summary, PEGylated silk nanoparticles were developed, characterized and tested as a 
potential anticancer drug delivery system. PEGylated silk nanoparticles showed excellent drug 
loading and release capacity and these nanoparticles were subsequently assessed for their in vitro 
antitumour efficacy. Here, we demonstrate the first example of silk nanoparticle combination 
therapy. These findings, when combined with prior in vitro data on silk, support a viable future 
for silk-based nanomedicines. 
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Supplementary Figure 1. Absorbance spectra of silkÕs amide I region after Fourier self-
deconvolution. Panel (A) untreated silk films, (B) autoclaved silk films, (C) native silk 
nanoparticles and (D) PEGylated silk nanoparticles. The heavy line represents the deduced 
absorbance band. The light lines represent the contributions to the amide I band and are marked 
as (A) α-helix, (B) β-sheet, (R) random coil, (SC) side chain and (T) turn.  
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Supplementary Figure 2. Encapsulation efficiency of native silk nanoparticles (50 mg) over a 
range of propranolol amounts (±SD, error bars are hidden in the plot-symbol when not visible).  
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Supplementary Figure 3. Zeta potential of drug loaded native and PEGylated silk nanoparticles. 
(A) Native and (B) PEGylated silk nanoparticles were loaded with propranolol (2.1 µg) and 
doxorubicin (0.01 µg). (Significant differences were determined with ANOVA followed by 
BonferroniÕs multiple comparison post hoc test, **P< 0.001, ±SD, n=3). 
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Supplementary Figure 4. In vitro cytotoxicity of freely diffusible doxorubicin, propranolol and 
drug combinations against MCF-7 breast cancer cells. (A) Growth inhibitory effect of 
combination of doxorubicin and propranolol in MCF-7 cell lines after 72 h exposure. (B) 
Isobologram of doxorubicin and propranolol. Experimental data point represented by square 
located close to the additive line; for doxorubicin (0.1 µg/ml) and propranolol (21 µg/ml) drug 
combination. (±SD, error bars are hidden in the plot-symbol when not visible n=3 independent 
experiments). 
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